Arax Advisory Partners’s Maravai LifeSciences MRVI Stock Holding History

Arax Advisory Partners’s Portfolio MRVI Stock Details MRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$7.33K	Buy	+1,175	New	+$5.07K	﹤0.01%	4470
2026 Q1	–	Sell	-15	Closed	-$49	–	4141
2025 Q4	$49	Sell	15 -824	-98%	-$2.77K	﹤0.01%	3920
2025 Q3	$2.41K	Buy	+839	New	+$2.14K	﹤0.01%	3074
2025 Q1	–	Sell	-4,063	Closed	-$22.1K	–	2907
2024 Q4	$22.1K	Sell	4,063 -1,509	-27%	-$9.71K	﹤0.01%	1171
2024 Q3	$46.3K	Buy	5,572 +1,332	+31%	+$11.5K	﹤0.01%	749
2024 Q2	$30.4K	Buy	+4,240	New	+$36.6K	﹤0.01%	832
2023 Q1	–	Sell	-118	Closed	-$1.69K	–	1300
2022 Q4	$1.69K	Hold	118	–	–	﹤0.01%	971
2022 Q3	$3K	Hold	118	–	–	﹤0.01%	917
2022 Q2	$3K	Hold	118	–	–	﹤0.01%	902
2022 Q1	$4K	Hold	118	–	–	﹤0.01%	836
2021 Q4	$5K	Hold	118	–	–	﹤0.01%	765
2021 Q3	$6K	Sell	118 -145	-55%	-$7.07K	﹤0.01%	738
2021 Q2	$11K	Buy	+263	New	+$10.2K	﹤0.01%	653

Other funds holding MRVI

GTCR LLC Chicago, Illinois $3.91B AUM 14.64% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return

1WCM

12 West Capital Management New York $535M AUM 25.99% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

OAM

Ophir Asset Management Sydney, Australia $1.22B AUM 100.03% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return

Arax Advisory Partners's MRVI Position: Q2 2026 in Review

Arax Advisory Partners opened a new position in Maravai LifeSciences (MRVI) in Q2 2026: 1,175 shares worth $7.33K. The stake represents ﹤0.01% of the portfolio and ranks #4470 among its holdings. This is a return to the name: Arax Advisory Partners previously reported a position in MRVI as recently as Q4 2025.

Arax Advisory Partners first reported a position in MRVI in Q2 2021 and has held it in 13 quarters since. The position peaked at $46.3K in Q3 2024. 178 funds tracked by Wall St. Rank hold MRVI as of Q2 2026.

Arax Advisory Partners held 1,175 shares of Maravai LifeSciences worth $7.33K as of Q2 2026.
Maravai LifeSciences was a new Arax Advisory Partners position in Q2 2026.
Maravai LifeSciences made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #4470 holding.
Arax Advisory Partners first reported a position in Maravai LifeSciences in Q2 2021 and has held it in 13 quarters since.
Arax Advisory Partners's Maravai LifeSciences position peaked at $46.3K in Q3 2024.
178 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.